Answers are grounded in this paper and cite their sources.
Scoping review maps pharmacological interventions and emerging targets in temporomandibular joint disorders, highlighting knowledge gaps.
BACKGROUND: Temporomandibular joint disorders (TMJDs) are painful musculoskeletal conditions affecting the temporomandibular joint, for which pharmacological options remain incompletely defined. OBJECTIVE: This scoping review mapped the extent, range, and nature of research on TMJD pharmacological research (2014-2025), examining current interventions and identified emerging therapeutic targets. METHODS: A systematic search across PubMed, ScienceDirect, Scopus, and Web of Science (2014-2025), included clinical andanimal studies. Data were synthesized following JBI scoping review methodology and reported per PRISMA-ScR guidelines. RESULTS: Seventy-eight studies met inclusion criteria (21 primary human studies, 34 reviews, and 23 animal studies). Eight pharmacological categories were identified: hyaluronic acid (10 studies), corticosteroids (4), NSAIDs and analgesics (19), bisphosphonates (3), drug delivery mechanisms (10), emerging agents (9), comparative studies (10), and general reviews (13). CONCLUSIONS: Evidence gaps persist in standardized outcome measures, long-term efficacy, and subtype-specific prescribing. Rigorous clinical trials integrating diagnostic phenotypingare essential to advance individualized pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Skármeta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: